Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer
Open Access
- 25 May 2004
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 91 (1), 30-36
- https://doi.org/10.1038/sj.bjc.6601897
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood, 2002
- DIFFERENTIAL EFFECTS BETWEEN MARIMASTAT, A TNF-α CONVERTING ENZYME INHIBITOR, AND ANTI-TNF-α ANTIBODY ON MURINE MODELS FOR SEPSIS AND ARTHRITISCytokine, 2002
- The significance of CD105, TGFβ and CD105/TGFβ complexes in coronary artery diseaseAtherosclerosis, 2000
- Prevention of Venous Thromboembolism in Cancer PatientsSeminars in Thrombosis and Hemostasis, 1999
- The effect of renin–angiotensin system inhibitors on pro‐ and anti‐inflammatory cytokine productionImmunology, 1998
- Basic-Fibroblast-Growth-Factor-Mediated de novo Angiogenesis Is More Effectively Suppressed by Low-Molecular-Weight than by High-Molecular-Weight HeparinInternational Journal of Microcirculation, 1996
- Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitorNature, 1994
- Processing of tumour necrosis factor-α precursor by metalloproteinasesNature, 1994
- Lower mortality in cancer patients treated with low-molecular-weight versus standard heparinThe Lancet, 1992
- Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of CortisoneScience, 1983